PUT - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 05:36:59 19/06/2024 pm IST | ||
| 3.51 EUR | -25.16% |
|
| Current month | -58.05% | ||
| 1 month | -68.57% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 19/24/19 | 3.51 | -25.16% |
| 18/24/18 | 4.69 | +3.76% |
| 17/24/17 | 4.52 | -14.39% |
| 14/24/14 | 5.28 | -0.75% |
| 13/24/13 | 5.32 | -20.24% |
Delayed Quote Deutsche Boerse AG
Last update June 19, 2024 at 05:36 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0ESG |
| ISIN | DE000VD0ESG0 |
| Date issued | 15/02/2024 |
| Strike | 933.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 16.45 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 19.64 € |
|---|---|
| Lowest since issue | 3.51 € |
| Spread | 0.42 € |
| Spread % | 10.40% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
891.5
USD
Average target price
855.4
USD
Spread / Average Target
-4.05%
- Stock Market
- Certificates
- Certificat
